Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
Flupentixol/melitracen is a fixed-dose combination of a thioxanthene antipsychotic (flupentixol) and a tricyclic antidepressant (melitracen). It is marketed under various brand names (e.g., Deanxit) in many countries, though it is not FDA-approved in the United States.
## Primary Indications
* Management of mild to moderate anxiety, depression, and apathy.
* Psychosomatic disorders manifesting with anxiety or depressive symptoms.
## Adult Dosing
* **Standard Starting Dose:** 1 tablet (0.5 mg flupentixol / 10 mg melitracen) twice daily (morning and noon).
* **Maintenance:** 1 tablet once daily in the morning may be sufficient for some patients.
* **Maximum Dose:** 4 tablets per 24 hours. Prolonged use at high doses should be avoided due to the accumulation of flupentixol.
## Pediatric Dosing
* **Safety/Efficacy:** Not established. Use is generally contraindicated or strongly discouraged in children and adolescents under 18 years of age.
## Dose Adjustments
* **Renal/Hepatic Impairment:** Use with caution. No standardized adjustment protocols exist; clinical judgment and lower starting doses are recommended.
* **Elderly:** Use the lowest effective dose; start with 1 tablet in the morning. Monitor closely for orthostatic hypotension and anticholinergic effects.
## Contraindications
* Hypersensitivity to flupentixol or melitracen.
* Acute alcohol, barbiturate, or opioid intoxication.
* Comatose states.
* Bone marrow depression.
* Recent myocardial infarction or third-degree AV block.
* Untreated narrow-angle glaucoma.
* Urinary retention.
* Hypertrophy of prostate.
## Adverse Effects
* **Common:** Dry mouth, dizziness, insomnia, tremor, and restlessness.
* **Serious:** Extrapyramidal symptoms (EPS), tardive dyskinesia (rare with low-dose flupentixol), hypotension, tachycardia, cardiac arrhythmias (due to melitracen), and serotonin syndrome (if combined with SSRIs).
## Key Drug Interactions
* **MAO Inhibitors:** Risk of hypertensive crisis (wait at least 14 days after stopping MAOI).
* **CNS Depressants:** Enhances sedation with alcohol, benzodiazepines, and opioids.
* **Antihypertensives:** Potential for additive hypotensive effects.
* **CYP450 Inducers/Inhibitors:** Melitracen is metabolized by various CYP enzymes; plasma levels may be affected by inhibitors like fluoxetine or paroxetine.
## Monitoring
* **Baseline:** ECG (especially in elderly or patients with cardiac history).
* **Ongoing:** Liver function tests periodically; monitor for signs of motor abnormalities (AIMS scale); blood pressure monitoring.
## Clinical Pearls
* **Timing:** Avoid taking the second dose in the evening as the melitracen component can cause insomnia.
* **Duration:** Therapy should be limited to the minimum effective duration; taper to discontinue to avoid withdrawal symptoms related to the TCA component.
* **Lack of Consensus:** Due to the combination of an antipsychotic and an antidepressant, practice varies significantly by region. Always consult local clinical formularies or prescribing guidelines, as they may prioritize SSRIs or other classes for first-line treatment of anxiety/depression.
***
**Educational Disclaimer:** This information is for educational purposes only. Always verify current prescribing information, contraindications, and local institutional policies with a licensed physician or the official product monograph before prescribing or administering medication.
